On March 31, 2011, the United District Court for the Eastern District of Texas (Judge Ward) entered a judgment against Johnson & Johnson and Cordis Corporation in the amount of $583 million. The judgment stems from a patent infringement action filed by Bruce Saffran, M.D., Ph.D. against Johnson & Johnson and Cordis over drug eluting stents (this is not the first time Dr. Saffran has won a large patent case against a medical device maker for drug eluting stents as he previously prevailed on a case against Boston Scientific for over $400 million which has since settled).
In upholding the jury verdict, the Court found that, based on the Court’s earlier claim construction (which the Court declined to reconsider), there was sufficient evidence to support the jury verdict of patent infringement. In reaching this conclusion, the Court noted the testimony of plaintiff’s expert and found that a reasonable jury could have relied on the testimony of plaintiff’s expert and that was sufficient to support the finding of infringement.
The Court also rejected defendants’ challenge to the validity of the patent and also noted that the parties had stipulated to use a preponderance of the evidence standard for prior art that was not before the patent office in light of the i4i v. Microsoft case that is currently pending before the United States Supreme Court. Such a strategic decision by the plaintiff eliminate a potential ground for reversal of this award in the event that the United States Supreme Court changes the burden of proof for validity challenges.